The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve
- PMID: 22095792
- DOI: 10.1093/humrep/der371
The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve
Abstract
Background: Poor ovarian response is a common clinical problem, affecting up to 26% of IVF cycles. For these women, addition of recombinant luteinizing hormone (rLH) to ovarian hyperstimulation with recombinant FSH has a beneficial effect on ongoing pregnancy rates, but its effect on the yield of top-quality embryos is unknown.
Methods: We conducted a randomized controlled trial in women expected to respond poorly under ovarian hyperstimulation during their first IVF cycle [all women aged 35-41 and women with FSH > 12 IU/ml and antral follicle count (AFC) ≤ 5]. Women were randomly allocated to rFSH and rLH (2:1 ratio) or rFSH alone (control group) after down-regulation with a GnRH agonist. The primary outcome was the proportion of top-quality embryos per woman on the day of transfer. Secondary outcomes were the number of stimulation days, the number of follicles ≥17 mm, the number of oocytes, the fertilization rate, the number of embryos, the number of women with ≥1 top-quality embryo, the biochemical, clinical and ongoing pregnancy rates and the miscarriage rate.
Results: There were 116 women allocated to the rLH group and 128 allocated to the control group. The proportion of top-quality embryos per woman was 17% in the rLH group and 11% in the control group [mean difference 0.06; 95% confidence interval (CI) -0.01-0.14]. In the rLH and control groups respectively, 47 (41%) and 41 (32%) women had at least one top-quality embryo on the day of transfer (relative risk: 1.3, 95% CI 0.91-1.77). The ongoing pregnancy rate was 13 versus 12% (relative risk: 1.1; 95% CI 0.57-2.16) for the rLH group compared with the control group.
Conclusions: This study found no significant difference in embryo quality after the addition of rLH to rFSH for ovarian stimulation in women with poor ovarian reserve.
Clinical trials identifier: NTR1457.
Similar articles
-
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.Cochrane Database Syst Rev. 2017 May 24;5(5):CD005070. doi: 10.1002/14651858.CD005070.pub3. Cochrane Database Syst Rev. 2017. PMID: 28537052 Free PMC article. Review.
-
[Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].Zhonghua Fu Chan Ke Za Zhi. 2013 Nov;48(11):838-42. Zhonghua Fu Chan Ke Za Zhi. 2013. PMID: 24444561 Chinese.
-
Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.Hum Reprod. 2005 Feb;20(2):390-6. doi: 10.1093/humrep/deh625. Epub 2004 Dec 2. Hum Reprod. 2005. PMID: 15576390 Clinical Trial.
-
Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.Fertil Steril. 2008 Mar;89(3):546-53. doi: 10.1016/j.fertnstert.2007.03.088. Epub 2007 May 29. Fertil Steril. 2008. PMID: 17531989 Clinical Trial.
-
Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles.Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005070. doi: 10.1002/14651858.CD005070.pub2. Cochrane Database Syst Rev. 2007. PMID: 17443569 Updated. Review.
Cited by
-
Homocysteine Level Related to Age Is Associated With Embryo Quality in Women Who Had IVF With Diminished Ovarian Reserve.Front Reprod Health. 2022 Jul 11;4:886277. doi: 10.3389/frph.2022.886277. eCollection 2022. Front Reprod Health. 2022. PMID: 36303650 Free PMC article. No abstract available.
-
Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review.Front Endocrinol (Lausanne). 2022 Aug 1;13:907249. doi: 10.3389/fendo.2022.907249. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35979440 Free PMC article. Review.
-
Improving Implantation Rate in 2nd ICSI Cycle through Ovarian Stimulation with FSH and LH in GNRH Antagonist Regimen.Rev Bras Ginecol Obstet. 2021 Oct;43(10):749-758. doi: 10.1055/s-0041-1736306. Epub 2021 Nov 16. Rev Bras Ginecol Obstet. 2021. PMID: 34784631 Free PMC article.
-
Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.Reprod Biol Endocrinol. 2021 Jun 21;19(1):91. doi: 10.1186/s12958-021-00759-4. Reprod Biol Endocrinol. 2021. PMID: 34154604 Free PMC article.
-
Human amnion-derived mesenchymal stem cells improved the reproductive function of age-related diminished ovarian reserve in mice through Ampk/FoxO3a signaling pathway.Stem Cell Res Ther. 2021 Jun 2;12(1):317. doi: 10.1186/s13287-021-02382-x. Stem Cell Res Ther. 2021. PMID: 34078462 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
